Business Context and Reporting Period
This Form 8-K filing by Dermata Therapeutics, Inc. (DRMA) covers the period ending May 20, 2024. The Company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California. Its common stock and warrants trade on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing matter rather than financial performance.
Material Changes
On May 20, 2024, the Company received notice from Nasdaq that it was not in compliance with Listing Rule 5550(a)(4) due to having fewer than 500,000 publicly held shares. However, based on additional information provided by the Company, Nasdaq confirmed on May 24, 2024, that the Company had regained compliance, and the listing matter was closed.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general business risks. The primary contingency addressed was the temporary failure to meet the minimum publicly held share requirement for continued listing on Nasdaq, which has been resolved.
Investor Verification Checklist
- Verify the current number of publicly held shares to ensure continued compliance with Nasdaq Listing Rule 5550(a)(4).
- Confirm that no further correspondence regarding delisting has been received since May 24, 2024.
- Review the Company's most recent 10-Q or 10-K for actual financial metrics, as this 8-K does not contain them.